Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
1 hedge funds and large institutions have $0 invested in Pear Therapeutics, Inc. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 52 closing their positions.
98% less funds holding
Funds holding: 53 → 1 (-52)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $20.7M → $0 (-$20.7M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 52
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$6.83M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$4.27M |
| 3 |
SoftBank Group
Tokyo,
Japan
|
-$3.09M |
| 4 |
AV
Arboretum Ventures
Ann Arbor,
Michigan
|
-$2.77M |
| 5 |
BlackRock
New York
|
-$857K |
PEAR Hedge Fund Activity: Q2 2023 in Review
1 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2023, worth a combined $0 — down 100% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of PEAR and 0 opened new positions — a net loss of 52 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Temasek Holdings, exiting entirely with an estimated $6.83M sold.
- 1 institutional investor held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2023, down from 53 in Q1 2023.
- Funds reported $0 of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2023 and 52 closed out, a net change of -52 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2023 was Temasek Holdings, an estimated $6.83M sold.
Based on aggregated 13F filings for Q2 2023.